阿斯利康的T790M牛逼新药AZD9291的1期临床结果出来了

Leerink Swann maintained an Outperform rating on Clovis Oncology (NASDAQ: CLVS) with a price target of $88.00. Comments follows data from AstraZeneca's (NYSE: AZN) AZD-9291.
LEERINK SWANN（医药界投行）保持对于CLOVIS ONCOLOGY的股票评级，目标股价为88美金。消息来源于阿斯利康的AZD9291。

"At ESMO, AZD-9291 had positive data and represents strong competition to CLVS' CO-1686 in a large sand box narrowly defined by T790M+ patients and broadly by the entire nonsmall cell lung cancer (NSCLC) market," said analyst Marko Kozul.
在欧洲肿瘤内科学会上,AZD9291的数据表现不俗并且在大量的T790M阳性病人数据中及拓展到整个非小细胞癌（治疗）市场中，其与CLVS的CO1686相比具有很强的竞争性。分析师MARKO KOZUL如是说。
"Net-net, a MEDACorp key opinion leader (KOL) at ESMO believes AZN (MP) and CLVS are in a close first-to-market race, with resources likely to define the winner."
会上Net-net作为一名医药企业的关键意见领袖，他相信阿斯利康和CLVS处于同一起跑线来竞争谁会先投入市场，因为他们两者都具备相当的条件成为胜者。

"ESMO AZD-9291 data demonstrate it is a strong competitor even at the 20mg dose, with potential improvement from further dose escalation just as CLVS may benefit from dose escalation with its 500mg BID bromide salt formulation and beyond. ）
AZD9291数据显示其即使在20MG剂量时，（与CO1686相比）仍是很强的竞争者，当AZD9291在20MG剂量时，其在剂量提升上更具有潜在的改进性，正如CLVS可能获益于其从500MG的每日两次溴盐制剂乃至更多剂量开始增量。Positive Rucaparib data at ESMO continue to de-risk this compound, which should generate more value in 2014+.
学会上，另一款RUCAPARIB的不俗数据持续减少这一化学合成物的风险性，其在2014年应该会产生更高的价值。
Assuming AZD-9291/CO-1686 split the T790M+ market, our DCF would still yield $68, with upside from front-line NSCLC penetration and Rucaparib.
假设AZD9291和CO1686将各分T790M阳性市场，从非小细胞肺癌一线的渗透及RECAPARIB，我们的现金流折算估值预计能获利68美金（应该是每股获利）
We reiterate our Outperform rating, $88 price target (PT) and would take advantage of any volatility going into World Lung at the end of
October," he added.
我们重复评估，目标股价为88美金，并将利用任何稍纵即逝的可能性在十月底前进入世界肺部（基金）。

谢谢老马和υīСКī ！

马哥看懂了   我不懂呵呵

nbhstqw 发表于 2013-10-3 13:18

                               
登录/注册后可看大图

这药是不是易瑞沙耐药后的药??

看着是， 严密关注

关注！希望是每位患者的福音！

老马，太牛了，消息超前，给大家不断带来希望

好消息，期待早日用于临床。

是不是仅限肺癌用？肝癌那用吗？

关注！希望是每位患者的福音！

  
"The ESMO abstract details data for 27 enrolled patients with 6 patients across 3 dose escalation cohorts and 9 patients in a T790M+ expansion cohort.
欧洲临床肿瘤协会年会概述详细表述了（经AZD9291临床试药的）数据，该数据招募27名病患，其中6名病患接受了3个不同剂量的增量用药，9名病患为T790M阳性。
In terms of safety, the most common adverse events were Grade-1 (G-1) with maximum G-1 diarrhea and rash toxicity in the 20, 40 and 80mg cohorts.
就安全性而言，最常见的不良事情为等级1，包括等级最强的1级腹泻和剂量在20，40，80MG时皮疹毒性。
Diarrhea and rash are also toxicities typical of Iressa and Tarceva," said Kozul.
腹泻及皮疹也是易瑞沙和特罗凯的常见毒性，KOZUL说。

"In terms of efficacy, 1) for the 20mg cohort, 2/6 patients cohort demonstrated a partial response (PR) and both of these patients had confirmed T790M+ status;
就有效性而言，1）剂量在20MG时，6名病患中有2名给出了一个部分反馈（反馈有效），而他们两者经确认为T790M阳性。
2) for the 40mg cohort, 2/6 patients demonstrated 2 unconfirmed PRs and the T790M status of these patients in unknown;
2）剂量在40MG时，6名病患中有2名给出2个不确定的部分反馈，他们的T790M状态暂不清楚。
3) for the 80mg cohort, no data have yet been provided. Dose escalation continues as well as recruitment into the T790M+ expansion cohort," he added.
3）剂量在80MG时，尚没有数据提供。增量试验仍在进行中，T790M阳性扩增病员也在招募中。
========================================
Response data for AZN’s drug AZD9291 includes 2 confirmed partial responses at the first (20 mg/day) dose level in
patients whose NSCLC tumors harbored a T790M mutation and 2 unconfirmed responses in the 40 mg dose (T790M
status unknown).
阿斯利康的AZD9291的反馈数据包括2条已经确认的部分反馈，这两天反馈基于第一阶段（20MG/每天），这两名病人为非小细胞肺癌且T790M变异。另2条不确定的反馈基于40MG的剂量（T790M状态未知）
To date, 27 patients have been treated across 20, 40 and 80 mg dose levels (n = 18) and in T790M+
expansion cohorts (n = 9) and no dose limiting toxicities have been reported. Both dose escalation and recruitment into a
T790M expansion cohort are ongoing.
目前，27名病人已经接受了20，40和80MG的剂量（N=18）和T790M阳性扩增组群（N=9），并且没有报告有剂量限制毒性产生。这一增量试验及T790M阳性扩增的人员招募仍在进行中。